ONCT Company Profile and Key Details

Q: Who are the executives of ONCT?

Mr. Pablo UrbanejaSenior Vice President of Corporation Devel.Dr. Gunnar F. Kaufmann Ph.D.Chief Scientific OfficerMr. Richard G. Vincent CPAChief Financial Officer & TreasurerMr. Chase C. LeavittGen. Counsel & Sec.Dr. Rajesh Krishnan Ph.D.Chief Technology OfficerDr. Steven Hamburger Ph.D.Senior Vice President of Regulatory Affairs & Quality AssuranceDr. Salim Yazji M.D.Chief Medical OfficerDr. James B. Breitmeyer M.D., Ph.D.Pres, Chief Executive Officer & Director

NASDAQ : ONCT

Oncternal Therapeutics

$0.53

-0.1674-24.12%

At Close 4:00 PM

Not Actively Trading

66.02

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Oncternal Therapeutics, Inc. (ONCT) stock declined over -24.12%, trading at $0.53 on NASDAQ, down from the previous close of $0.69. The stock opened at $0.70, fluctuating between $0.53 and $0.70 in the recent session.

Stock Snapshot

0.694

Prev. Close

1.56M

Market Cap

0.5266

Day Low

-0.04504704875962361

P/E Ratio

-11.69

EPS (TTM)

-10.91

Cash Flow per Share

0.7

Open

2.96M

Number of Shares

0.7

Day High

91.45%

Free Float in %

10.19

Book Value

644.14K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close
Dec 31, 2024	0.53	0.53	0.53	0.53
Dec 30, 2024	0.53	0.53	0.53	0.53
Dec 27, 2024	0.53	0.53	0.53	0.53
Dec 26, 2024	0.53	0.53	0.53	0.53
Dec 24, 2024	0.53	0.53	0.53	0.53
Dec 23, 2024	0.53	0.53	0.53	0.53
Dec 20, 2024	0.53	0.53	0.53	0.53
Dec 19, 2024	0.53	0.53	0.53	0.53
Dec 18, 2024	0.53	0.53	0.53	0.53
Dec 17, 2024	0.53	0.53	0.53	0.53
Dec 16, 2024	0.53	0.53	0.53	0.53
Dec 13, 2024	0.53	0.53	0.53	0.53
Dec 12, 2024	0.53	0.53	0.53	0.53
Dec 11, 2024	0.53	0.53	0.53	0.53
Dec 10, 2024	0.53	0.53	0.53	0.53
Dec 09, 2024	0.53	0.53	0.53	0.53
Dec 06, 2024	0.53	0.53	0.53	0.53
Dec 05, 2024	0.53	0.53	0.53	0.53
Dec 04, 2024	0.53	0.53	0.53	0.53
Dec 03, 2024	0.53	0.53	0.53	0.53

Contact Details

San Diego, CA 92130

United States

https://www.oncternal.com 858 434 1113

About Company

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.

Stock Peers

REGN

9.14+1.17%

Regeneron Pharmaceuticals, Inc.$790.81 ARGX

-10.16-1.32%

argenx SE$756.76 UTHR

9.92+1.97%

United Therapeutics Corporation$513.82 VRTX

-10.8-2.17%

Vertex Pharmaceuticals Incorporated$486.03 MDGL

3.62+0.84%

Madrigal Pharmaceuticals, Inc.$435.62 PRAX

-6.16-1.83%

Praxis Precision Medicines, Inc.$330.59 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-7.85-2.36%

Alnylam Pharmaceuticals, Inc.$325.07 KRYS

-16.83-6.11%

Krystal Biotech, Inc.$258.81 ASND

8.59+3.68%

Ascendis Pharma A/S$242.09

Company Overview

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) closed at $0.53 USD, losing -$0.17 (-24.12%) from the previous close of $0.69. The stock is currently trading near its 52-week low $0.53 and $10.61. With a market capitalization of about $1.56 million, Oncternal Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.36). Key stats such as the average daily volume over the past year has been around 62.27 thousand shares, trading with heavier-than-usual volume. Headquartered in San Diego, CA, Oncternal Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO James B. Breitmeyer, the company employs approximately 27 people and listed since February 03, 2004. Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 -52.91%, SMA50 -59.05%, SMA200 -90.96%). The stock’s 14-day RSI is 25.19 (weak momentum), while the ATR of 0.17 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -95.99% below its high and over 0.0% above its low.

Valuation Metrics

Oncternal Therapeutics, Inc. trades at a P/E ratio of -0.04, slightly below the S&P 500 average, with a price-to-sales ratio of 1.99 and a price-to-book ratio of 0.05 suggesting the stock is closer to book value. The P/FCF stands at -0.05, also above market averages.

Dividend & Fair Value

Oncternal Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.12. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Oncternal Therapeutics, Inc. generated EPS of -$11.69 over the past year. Five-year average earnings growth is 18.19%. Wall Street analysts project EPS growth of 0.0% annually over the next five years. The latest quarter delivered EPS of -$2.86. The next quarter is forecast at $nan. Next year's EPS is expected at $16.04. Oncternal Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2024, missed forecasts by -10.34%. The prior quarter beat by -4.57%. Over the last six quarters, Apple has recorded several small beats. These include -11.76% in August 10, 2023.

Shareholding & Insider Activity

Oncternal Therapeutics, Inc. has 2.96 million shares outstanding. The public float is 2.71 million shares, elevated short interest at 0.50% of float. This equals 14.21 thousand shares. The short ratio is 0.09 days. Institutional investors hold 13.3% of the float. Insiders own 9.23%. SCHULER JACK W holds 6.17 million shares, HYDE JOSEPH R III has 5.99 million shares and STEINER MITCHELL SHUSTER has 1.95 million shares.

Financial & Profitability Overview

Over the trailing twelve months, Oncternal Therapeutics generated $785.00K in revenue, or $0.27 per share. Gross margin was -3690.19%, operating margin -5313.89%, and net profit margin -5029.17%. Returns are negative, with ROA at -107.49% and ROE at -131.37%.
On valuation metrics, Oncternal Therapeutics trades at a P/E of -0.04, P/S of 1.99 and P/B of 0.05. The current ratio is 6.94 and quick ratio is 6.94. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 279.78 days. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -101.14.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Oncternal Therapeutics posted revenue of $785.00K, down slightly from $0.00 in the prior quarter. Gross profit was - $28.97M (margin -3690.19%). Operating income was - $41.71M (margin -5313.9%). Net income was- $39.48M (EPS - $13.43).
The company ended the quarter with $34.26M in cash and short-term investments, a total debt of $318.00K, and net debt of - $6.38M. Total assets were $36.73M, with equity of $30.05M. Financials further reflected weakness, with operating cash flow of - $32.16M, free cash flow of - $32.16M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Oncternal Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -94.3%, with price expected at $0.03 by January 14, 2025, within a range of $0.00 to $0.21 3-Month Outlook: Projected rise of 1926.21%, reaching $10.67 by March 05, 2025, with a range of $9.81 to $11.58. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by December 05, 2025, within a range of $0.00 to $3.49.

Key Takeaways

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) shares are flat -1.16% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Oncternal Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.04. Analyst sentiment is cautious, with the majority of ratings in Market Perform territory and a mean price target of $9.83, suggesting 1766.69% upside. Our AI forecast model points to short-term weakness (-94.3% over two weeks), a medium-term rise (1926.21% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Oncternal Therapeutics, Inc. (ONCT) stock price?

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) stock price is $0.53 in the last trading session. During the trading session, ONCT stock reached the peak price of $0.70 while $0.53 was the lowest point it dropped to. The percentage change in ONCT stock occurred in the recent session was -24.12% while the dollar amount for the price change in ONCT stock was - $0.17.

ONCT's industry and sector of operation?

The NASDAQ listed ONCT is part of Biotechnology industry that operates in the broader Healthcare sector. Oncternal Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ONCT?

Mr. Pablo Urbaneja
Senior Vice President of Corporation Devel.
Dr. Gunnar F. Kaufmann Ph.D.
Chief Scientific Officer
Mr. Richard G. Vincent CPA
Chief Financial Officer & Treasurer
Mr. Chase C. Leavitt
Gen. Counsel & Sec.
Dr. Rajesh Krishnan Ph.D.
Chief Technology Officer
Dr. Steven Hamburger Ph.D.
Senior Vice President of Regulatory Affairs & Quality Assurance
Dr. Salim Yazji M.D.
Chief Medical Officer
Dr. James B. Breitmeyer M.D., Ph.D.
Pres, Chief Executive Officer & Director

How ONCT did perform over past 52-week?

ONCT's closing price is 0% higher than its 52-week low of $0.53 where as its distance from 52-week high of $10.61 is -95.04%.

How many employees does ONCT have?

Number of ONCT employees currently stands at 27.

Link for ONCT official website?

Official Website of ONCT is: https://www.oncternal.com

How do I contact ONCT?

ONCT could be contacted at phone 858 434 1113 and can also be accessed through its website. ONCT operates from 12230 El Camino Real, San Diego, CA 92130, United States.

How many shares of ONCT are traded daily?

ONCT stock volume for the day was 644.14K shares. The average number of ONCT shares traded daily for last 3 months was 62.27K.

What is the market cap of ONCT currently?

The market value of ONCT currently stands at $1.56M with its latest stock price at $0.53 and 2.96M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	27
Beta	1.36
Sales or Revenue	$785.00K
5Y Sales Change%	-0.647%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ONCT Company Profile and Key Details

Oncternal Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Stock Snapshot

Technical Performance

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Dividend & Fair Value

Company Overview

Price Forecast & Outlook

Key Takeaways

Valuation Metrics